Homozygosity for TYK2 P1104A underlies tuberculosis in about 1% of patients in a cohort of European ancestry

G Kerner, N Ramirez-Alejo… - Proceedings of the …, 2019 - National Acad Sciences
The human genetic basis of tuberculosis (TB) has long remained elusive. We recently
reported a high level of enrichment in homozygosity for the common TYK2 P1104A variant in …

Discovery of tyrosine kinase 2 (TYK2) inhibitor (PF-06826647) for the treatment of autoimmune diseases

BS Gerstenberger, C Ambler, EP Arnold… - Journal of Medicinal …, 2020 - ACS Publications
Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family that regulates signal
transduction downstream of receptors for the IL-23/IL-12 pathways and type I interferon …

Abnormalities of the type I interferon signaling pathway in lupus autoimmunity

S Gallucci, S Meka, AM Gamero - Cytokine, 2021 - Elsevier
Type I interferons (IFNs), mostly IFNα and IFNβ, and the type I IFN Signature are important in
the pathogenesis of Systemic Lupus Erythematosus (SLE), an autoimmune chronic …

Discovery of BMS-986202: a clinical Tyk2 inhibitor that binds to Tyk2 JH2

C Liu, J Lin, C Langevine, D Smith, J Li… - Journal of Medicinal …, 2020 - ACS Publications
A search for structurally diversified Tyk2 JH2 ligands from 6 (BMS-986165), a pyridazine
carboxamide-derived Tyk2 JH2 ligand as a clinical Tyk2 inhibitor currently in late …

TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases

M Gonciarz, K Pawlak-Buś, P Leszczyński… - …, 2021 - Taylor & Francis
JAKs are intracellular protein tyrosine kinases that, through activation of STATs, are
responsible for signal transduction pathways that regulate cellular responses to numerous …

Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders

P Xu, P Shen, B Yu, X Xu, R Ge, X Cheng… - European Journal of …, 2020 - Elsevier
Abstract The Janus kinases or JAKs are a family of intracellular tyrosine kinases that play an
essential role in the signaling of numerous cytokines that have been implicated in the …

[HTML][HTML] Thromboembolic adverse drug reactions in Janus kinase (JAK) inhibitors: does the inhibitor specificity play a role?

PJ Kotyla, M Engelmann, J Giemza-Stokłosa… - International journal of …, 2021 - mdpi.com
Recent advances in immunology enabled the characterization of several signal transmitting
pathways responsible for proper cytokine and chemokine signaling. Among them, Janus …

Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature

H Li, H Wang, G Qiao, Y Liu, F Zhang, F Pan - International …, 2023 - Elsevier
Bullous pemphigoid (BP) and psoriasis are both immune-related skin diseases. Still, the
comorbidities between the two are rare, and there is no consensus on the optimal treatment …

Development and therapeutic implications of tyrosine kinase 2 inhibitors

K Zhang, K Ye, H Tang, Z Qi, T Wang… - Journal of Medicinal …, 2023 - ACS Publications
Janus kinases (JAKs) are central components in cytokine signaling pathways. A number of
small molecule JAK inhibitors have been approved to treat a wide range of inflammatory and …

[HTML][HTML] TYK2: an upstream kinase of STATs in cancer

K Wöss, N Simonović, B Strobl, S Macho-Maschler… - Cancers, 2019 - mdpi.com
In this review we concentrate on the recent findings describing the oncogenic potential of the
protein tyrosine kinase 2 (TYK2). The overview on the current understanding of TYK2 …